Traws Pharma, Inc. (TRAW)의 가격은 얼마입니까?

Traws Pharma, Inc. (TRAW)의 가격은 $0.55입니다.

Traws Pharma, Inc. (TRAW)의 시가 총액은 무엇입니까?

Traws Pharma, Inc. (TRAW)의 시가 총액은 $8.38M입니다.

Traws Pharma, Inc. (TRAW) 영업이익률

Traws Pharma, Inc., a biopharmaceutical firm in the clinical development stage, is dedicated to creating novel small-molecule medications delivered orally to combat both respiratory viral infections and various forms of cancer. Its pipeline includes experimental treatments specifically designed to overcome drug resistance in influenza and COVID-19. These promising candidates include TRX01 (travatrelvir), an Mpro/3CL inhibitor currently undergoing development for COVID-19, and TRX100 (viroxavir), an endonuclease inhibitor advancing through trials for pandemic influenza. Additionally, Traws Pharma's oncology portfolio features narazaciclib, a multi-kinase CDK4/6 inhibitor. This compound is presently in Phase 1/2 clinical trials in cancer patients, being evaluated both independently and in conjunction with letrozole, with the goal of establishing the recommended Phase 2 dosage for future work in endometrial cancer. The company is also investigating oral rigosertib, exploring its potential as a standalone therapy or in combination regimens across diverse cancer types. Originally established in 1998 as Onconova Therapeutics, Inc., the company officially adopted its current name, Traws Pharma, Inc., in April 2024. Its corporate headquarters are located in Newtown, Pennsylvania.

연도	영업이익률	변화
제공된 날짜에 대한 데이터가 충분하지 않습니다.

연도

영업이익률

변화

제공된 날짜에 대한 데이터가 충분하지 않습니다.

회사	영업이익률	영업이익률 차이	국가
Vertex Pharmaceuticals Incorporated VRTX.US	38.59%	-	US
Argenx SE ARGX.US	28.81%	-	NL
Lonza Group AG LONN.SW	0.00%	-	CH
Samsung Biologics Co.,Ltd. 207940.KS	0.00%	-	KR
UCB S.A. UCB.BR	31.23%	-	BE

회사

영업이익률

영업이익률 차이

국가